Dyne Therapeutics(US:DYN) Globenewswire·2026-03-08 22:00Core Insights - Dyne Therapeutics announced positive data from the Phase 1/2 DELIVER clinical trial of z-rostudirsen, showing improvements in heart and lung function in patients with Duchenne muscular dystrophy (DMD) over 24 months, contrary to expected declines in natural history data [1][2] Group 1: Clinical Trial Results - The DELIVER trial demonstrated sustained functional improvement across multiple clinical measures, including cardiopulmonary function, in individuals with DMD amenable to exon 51 skipping [1][2] - Improvements in lung function, measured by Forced Vital Capacity Percent Predicted (FVC%p), were observed through 24 months, contrasting with expected declines from historical data [5] - Cardiac performance improvements were noted, including circumferential strain and left ventricular ejection fraction, both showing better outcomes than anticipated declines based on natural history data [5] Group 2: Treatment Profile - Z-rostudirsen is an investigational therapeutic designed to enable the production of near full-length dystrophin in muscle and the central nervous system, targeting DMD patients with specific genetic mutations [6] - The treatment has received multiple designations from the FDA, including Breakthrough Therapy and Fast Track, indicating its potential significance in addressing unmet medical needs in DMD [6] Group 3: Company Overview - Dyne Therapeutics focuses on developing therapeutics for genetically driven neuromuscular diseases, with ongoing clinical programs for DMD and myotonic dystrophy type 1, as well as preclinical programs for other muscular dystrophies [9] - The company aims to deliver functional improvements for individuals affected by these conditions, addressing both muscle and central nervous system challenges [9]